Skip to main navigation Skip to search Skip to main content

(+)-Hemipalmitoylcarnitinium Strongly Inhibits Carnitine Palmitoyltransferase-I in Intact Mitochondria

  • Richard D. Gandour
  • , On tai Leung*
  • , Anthony T. Greway
  • , Rona R. Ramsay
  • , Nóirín Nic a' Bháird
  • , Frank R. Fronczek
  • , Bret M. Bellard
  • , G. Kumaravel
  • *Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

The reaction of the methyl ester of (R)-norcarnitine with 1-bromo-2-heptadecanone produces (+)-6-[(methoxycarbonyl)methyl]-2-pentadecyl-4,4-dimethylmorpholinium bromide, 3, which hydrolyzes to (+)-6-(carboxylatomethyl)-2-pentadecyl-4,4-dimethylmorpholinium (hemipalmitoylcarnitinium, HPC) upon treatment with aqueous sodium hydroxide. Single-crystal X-ray analyses have confirmed the structures of (+)-HPC and 3. (+)-HPC inhibits carnitine palmitoyltransferase (CPT-I) activity for the forward reaction (palmitoyl-CoA + carnitine →) in intact mitochondria from rat heart and rat liver. (+)-HPC competitively (versus carnitine) inhibits CPT-I activity in both rat heart and liver mitochondria with Ki = 2.8 ± 0.5 and 4.2 ± 0.7 µM, respectively. As one of the strongest specific inhibitors of CPT-I, HPC is a potential therapeutic agent in myocardial ischemia and Type II diabetes.

Original languageEnglish
Pages (from-to)237-242
Number of pages6
JournalJournal of Medicinal Chemistry
Volume36
Issue number2
DOIs
Publication statusPublished - 1 Jan 1993

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of '(+)-Hemipalmitoylcarnitinium Strongly Inhibits Carnitine Palmitoyltransferase-I in Intact Mitochondria'. Together they form a unique fingerprint.

Cite this